Welcome to our dedicated page for Nuwellis news (Ticker: NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis stock.
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology and medical device company centered on precision fluid management for patients with cardio-renal conditions and fluid overload. News about Nuwellis frequently highlights clinical data, regulatory milestones, pediatric innovation, and business updates related to its Aquadex SmartFlow® ultrafiltration system and its Vivian™ pediatric continuous renal replacement therapy (CRRT) platform in development.
Readers of this NUWE news page can follow company announcements on topics such as new patents for extracorporeal safety technologies, NIH grant-supported development of the Vivian pediatric system, and multi-center registries like ULTRA-Peds that examine real-world Aquadex use in critically ill children. Nuwellis also issues news about clinical experiences at hospitals, including studies presented at nephrology conferences that explore Aquadex applications in acute kidney injury, post-cardiac-surgery fluid overload, and complex critical-care cases.
In addition to clinical and technology updates, Nuwellis regularly reports quarterly financial results, at-the-market equity offering arrangements, and other material events through press releases and SEC-referenced communications. These updates provide insight into revenue trends, product launches such as new catheter sizes or circuits, and strategic steps like focusing on U.S. market growth.
Investors, clinicians, and researchers can use this news feed to track how Nuwellis is advancing its Aquadex platform, expanding into pediatric and hospital-based outpatient settings, and progressing the Vivian pediatric CRRT system. Returning to this page allows users to monitor ongoing developments in the company’s cardio-renal strategy, intellectual property portfolio, and regulatory and clinical milestones associated with NUWE.
Nuwellis, Inc. announced the appointments of George Montague as Chief Financial Officer and Neil P. Ayotte as General Counsel and Chief Compliance Officer. Montague, effective June 28, 2021, brings over 20 years of healthcare finance experience, including prior roles at Smiths Medical and Medtronic. Ayotte, who joined on June 7, 2021, has extensive legal experience from his tenure at Bluestem Group and Medtronic. Their expertise is aimed at expanding access to Nuwellis's Aquadex SmartFlow® technology for fluid overload therapies.
Nuwellis, Inc. (Nasdaq: NUWE) has secured a three-year national contract with Premier, Inc. to promote its Aquadex SmartFlow® System for fluid management. This agreement allows Premier members to access special pricing for the therapy, which is the first in its newly defined Aquapheresis category. This collaboration aims to enhance the availability of ultrafiltration technology in hospitals across the U.S. Nuwellis focuses on innovative solutions for patients experiencing fluid overload, benefiting pediatric and critical care demographics.
Nuwellis, Inc. (NASDAQ: NUWE) announced on May 19, 2021, that its independent directors approved eight equity awards as an inducement for new employment, aligning with NASDAQ Listing Rule 5635(c)(4). The awards consist of options to purchase 6,227 shares at an exercise price of $3.63, which equals the stock's closing price on the grant date. These options will vest over four years and have a ten-year term. Nuwellis is focused on innovating medical devices for fluid overload treatment through its Aquadex SmartFlow system.
Nuwellis reported promising results for its Aquadex FlexFlow system in treating acutely decompensated heart failure (ADHF) patients. A study presented at the 2021 American College of Cardiology conference involved 30 patients, where 83% showed clinical symptom improvement. The mean fluid removal was 9.40L, with significant reductions in heart failure-related readmissions (p=0.017 at 60 days). These findings align with prior trials, affirming Aquadex's effectiveness without adverse renal impact. The company emphasizes its commitment to addressing heart failure challenges through innovative ultrafiltration therapy.
Nuwellis, Inc. (Nasdaq: NUWE) has expanded the availability of its Aquadex SmartFlow® System to Driscoll Children’s Hospital in Corpus Christi, Texas, aimed at pediatric patients experiencing fluid overload. This system allows for precise fluid removal using only 35 mL of blood, making it particularly advantageous for smaller patients. The technology is clinically proven for children weighing 20 kg or more, helping alleviate complications from conditions like heart and kidney failure. CEO Nestor Jaramillo emphasized their commitment to enhancing access to vital therapies.
Nuwellis, Inc. (Nasdaq: NUWE) reported its first-quarter results for 2021, showing revenue of $1.9 million, an 18% increase year-over-year. The company completed a rebranding from CHF Solutions, Inc. on April 27, 2021. Key highlights include increased Aquadex therapy utilization, the enrollment of the first pediatric patient in a clinical registry, and strong endorsements for a Category III CPT code application. Nuwellis ended the quarter with $27.9 million in cash and no debt, despite a net loss of $5.2 million.
Nuwellis, Inc. (NASDAQ:NUWE), formerly known as CHF Solutions, will announce its first quarter 2021 financial results on May 11, 2021, followed by a conference call at 9:00 AM ET. The session will include discussions on financial outcomes and business overview. Investors can access the live webcast through the company's website. Nuwellis specializes in developing medical devices aimed at alleviating fluid overload through innovative solutions, primarily focused on the Aquadex SmartFlow® system.
Summary not available.